Causes of Paraneoplastic Polycythemia
Paraneoplastic polycythemia results from autonomous tumor production of erythropoietin (EPO) independent of tissue oxygen levels, with renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma, uterine leiomyomas, pheochromocytoma, meningioma, and parathyroid carcinoma representing the established malignant and benign causes. 1, 2
Hypoxia-Independent Tumor-Associated Causes
The following tumors produce EPO autonomously, creating unregulated erythropoiesis regardless of tissue oxygenation:
Renal cell carcinoma is the most well-known cause of paraneoplastic polycythemia, though only 1–5% of cases present with overt erythrocytosis despite 34% showing EPO gene expression within tumor cells 1, 2, 3, 4, 5
Hepatocellular carcinoma produces EPO independently of hypoxia, with 23% of patients demonstrating elevated serum EPO concentrations even when hemoglobin remains normal due to concurrent malignancy-related bone marrow suppression 1, 2, 6
Cerebellar hemangioblastoma is the second most common tumor causing secondary polycythemia after renal cell carcinoma, with intratumoural EPO production confirmed by immunohistochemistry 1, 2, 3
Renal hemangioblastoma is a rare cause that can mimic renal cell carcinoma both clinically and histopathologically, making diagnosis challenging when erythrocytosis is present 3
Uterine leiomyomas (benign tumors) can produce EPO and cause paraneoplastic polycythemia 1, 2
Parathyroid carcinoma produces EPO autonomously through mechanisms independent of tissue oxygen levels 1
Pathophysiologic Mechanisms
Tumor cells of epithelial origin (particularly renal tubular cells in renal cell carcinoma) constitutively produce EPO through activation of hypoxia-inducible factor (HIF), with HIF-1α and/or HIF-2α driving EPO gene transcription even in normoxic conditions 4, 5
EPO gene expression in renal cell carcinoma is almost exclusively seen in clear cell histology and is always associated with HIF activation, though HIF activation alone is insufficient to explain why only a minority develop overt polycythemia 4
The discrepancy between high EPO gene expression (34% of renal cell carcinomas) and low prevalence of clinical polycythemia (1–5%) likely results from tumor-produced EPO that is either biologically inactive or counteracted by malignancy-related bone marrow suppression 4, 6
Diagnostic Approach to Suspected Paraneoplastic Polycythemia
When evaluating elevated hemoglobin/hematocrit for possible tumor-related causes:
Measure serum EPO level first – elevated EPO strongly suggests secondary polycythemia and prompts evaluation for hypoxia-independent tumor causes 1, 2
Exclude hypoxia-driven causes by checking arterial oxygen saturation, chest X-ray, and smoking history before attributing polycythemia to tumor production 1
Obtain abdominal ultrasound or CT to screen for renal cell carcinoma, hepatocellular carcinoma, and other EPO-producing tumors when EPO is elevated without hypoxia 1, 2
Check JAK2 V617F mutation if EPO is low or inappropriately normal, as this mutation is present in >95% of polycythemia vera cases and distinguishes primary from secondary causes 1, 2
Critical Diagnostic Pitfalls
Do not assume normal EPO excludes tumor-related polycythemia – EPO levels may normalize after hemoglobin stabilizes at a compensatory higher level, and some tumors produce biologically inactive EPO not detected by radioimmunoassay 1, 7, 6
Elevated serum EPO without overt polycythemia does not exclude tumor EPO production – advanced malignancy inhibits erythropoiesis despite high EPO levels, masking the expected erythrocytosis 6
Renal hemangioblastoma mimics renal cell carcinoma when presenting with erythrocytosis, creating diagnostic confusion both clinically and histopathologically; include it in the differential diagnosis of renal masses with polycythemia 3
EPO gene expression is far more common than clinical polycythemia in renal cell carcinoma (34% vs. 1–5%), suggesting paracrine or autocrine tumor effects beyond systemic erythrocytosis 4